Søgning
Søgning på udtrykket 'pseudomonas' giver 23 resultater
Nyt fra tidsskrifterne [+20] Aktuelle smitsomme sygdomme [3]
Nyt fra tidsskrifterne [+20]
Der er mere end 20 resultater, måske du vil se flere resultater her?
Nature
30.04.2025
BMC Infectious Diseases
29.04.2025
. Background. Carbapenem resistant Pseudomonas aeruginosa (P. aeruginosa) is a global health concern that poses a challenge to treat in health care facilities. Ceftazidim/avibactam and ceftolozane/tazobactam have a potential role in treatment of multi-drug resistant phenotypes including carbapenem resistant P. aeruginosa. Therefore, we aimed to assess the in vitro antimicrobial activity of ceftazidime/avibactam and ceftolozane/tazobactam against carbapenem-resistant P.
Virulence
26.04.2025
Volume 16, Issue 1, December 2025 .
International Journal of Infectious Diseases
24.04.2025
Diffuse panbronchiolitis (DPB), a chronic inflammatory disease of the small airways predominantly affecting East Asians. It is characterized by persistent Pseudomonas aeruginosa colonization, recurrent respiratory infections, and progressive respiratory failure. The 10-year survival rate is reported to exceed 90% with long-term erythromycin therapy; however, outcomes are significantly worse in patients infected with P.
FEMS Microbiology Reviews
17.04.2025
…onderantly commandeered approaches and classification of the known antiphage defense systems. A special focus is placed on the model bacterial pathogen, Pseudomonas aeruginosa in antiphage defense research. We explore the complexity and adaptability of these systems, which play crucial roles in genome evolution and adaptation of P. aeruginosa in response to an arsenal of diverse phage strains, emphasizing the importance of this organism as a key emerging model bacterium in recent antiphage defense research.
Virulence
12.04.2025
Volume 16, Issue 1, December 2025 .
Clinical Microbiology and Infection
6.04.2025
The Tranexamic acid to Reduce Infection after Gastrointestinal Surgery (TRIGS) trial is a placebo-controlled, multicentre, randomised trial examining whether tranexamic acid (TxA) reduces surgical site infections (clinicaltrials.gov NCT04192435). The investigational products consisted of TxA dissolved in sterile water in sealed glass vials and the placebo consisted of sterile water only in matching vials.
PLoS One Infectious Diseases
29.03.2025
by Zhongxu Duan, Jingqi Song, Mingru Zhang, Zhe Zhang, Nan Li, Yuqin Fu, Zhe Sun, Tiancheng Lu, Siyuan Li, Mingyue Cao, Qingyu Wang, Chunhui Sun, Xiuran Wang .
International Journal of Infectious Diseases
21.03.2025
Pseudomonas aeruginosa (P. aeruginosa) is a gram-negative bacterium and a conditioned or opportunistic pathogen. It is well-documented that P. aeruginosa is ubiquitous in natural environments, particularly in soil. The earliest reports of pneumonia caused by P. aeruginosa date back to 1917 [8]. P.
Clinical Microbiology and Infection
20.03.2025
While the introduction of novel β-lactams and/or combinations with β-lactamase inhibitors over the last decade is helping to mitigate the threat of extensively drug-resistant (XDR)/difficult to treat resistant (DTR) Pseudomonas aeruginosa infections, the problem is far from being solved, due to the capacity of this pathogen for developing resistance.
Infection and Immunity
11.03.2025
Infection and Immunity, Ahead of Print.
Infection and Immunity
19.02.2025
Infection and Immunity, Ahead of Print.
Infection
16.02.2025
. Abstract. . Introduction. Non-fermenting Gram-negative bacilli (NFGNB) other than Pseudomonas aeruginosa and Acinetobacter baumannii complex are pathogens of interest due to their ability to cause health-care associated infections and display complex drug resistance phenotypes. However, their clinical and microbiological landscape is still poorly characterized. . . .
Infection
16.02.2025
. Abstract. . Purpose. To determine predictors of mortality among patients with Pseudomonas aeruginosa bacteraemia. . . . Methods. Retrospective study. . . . Setting.
Infection
31.01.2025
…rformed a monocentric retrospective analysis of 361 lung transplantations performed in Homburg, Germany, between 1995 and 2020. All recipients with a main diagnosis of cystic fibrosis (n = 69) were stratified into two groups based on colonization with Pseudomonas aeruginosa in view of MRGN before transplantation: no colonization and colonization without (n = 23) or with (n = 46) resistance to three or four antibiotic groups (3MRGN/4MRGN).
Infection
31.01.2025
. Abstract. . Purpose. Bloodstream infections (BSIs) cause significant morbidity and mortality worldwide. Pseudomonas aeruginosa is an important microorganism in BSIs. The aim of this study was to analyze recent trends in the incidence and resistance rates of P. aeruginosa BSIs in Switzerland and its different linguistic regions. . . . Methods.
Infection
24.01.2025
. Abstract. . Purpose. Bloodstream infections caused by Pseudomonas aeruginosa (PABSI) in hematological patients are associated with high morbidity and mortality. We investigated the epidemiology, risk factors, and outcomes of PABSI at our center. . . . Methods. All adult hematological patients with PABSI between January 2013 and July 2023 were included.
Infection
24.01.2025
BMC Infectious Diseases
3.01.2025
. Abstract. . Background. Pseudomonas aeruginosa is one of the leading causes of nosocomial infections and the most common multidrug-resistant pathogen. This study aimed to determine antimicrobial resistance patterns, biofilm-forming capacity, and associated factors of multidrug resistance in P. aeruginosa isolates at two hospitals in Addis Ababa, Ethiopia. . . .
Clinical Microbiology and Infection
31.12.2024
To compile the evidence of sub-groups of patients with Pseudomonas aeruginosa (P. aeruginosa) infection from randomized control trials (RCTs) evaluating different definite antipseudomonal monotherapies for severe P.aeruginosa infection.
Aktuelle smitsomme sygdomme [3]
Aktuelle smitsomme sygdomme [3]
Eurosurveillance latest updates
11.04.2025
…ed Gram-negative bacteria were resistant. Percentage resistance per bacterial species varied over time, somewhat stabilising as testing was established, with between April 2019 and March 2020, 1.3% Escherichia coli (288/22,736; 95%CI: 1.1−1.4%), 12.6% Pseudomonas aeruginosa (690/5,495; 95%CI: 11.7−13.5%) and 6.1% of Klebsiella pneumoniae (314/5,179; 95%CI: 5.4−6.7%) being resistant. For 8,437 referred Enterobacterales, MIC determination found 11.5% (968/8,437; 95%CI: 10.8–12.2%) resistant.
Eurosurveillance latest updates
21.03.2025
…0.46; 95% CI: 0.30–0.69) decreased per 1° C temperature rise, while Pseudomonas aeruginosa (RR = 1.04; 95% CI: 1.03–1.05) and Legionella pneumophila infections (RR = 2.69; 95% CI: 1.11–6.53) increased. . . Conclusions. Temperature sensitivity of respiratory infections can vary with the specific pathogen type and subtype that causes the infection. As the climatic conditions will become warmer, public health policy makers should act to develop pathogen adaptation strategies. . . .
Eurosurveillance latest updates
8.03.2025
…ealth inequalities surrounding bacteraemia in England, to identify high-risk population groups and areas of intervention. . . Methods. We retrospectively analysed English surveillance data between 2018 and 2022 for Escherichia coli, Klebsiella species, Pseudomonas aeruginosa, and both meticillin-sensitive and resistant Staphylococcus aureus (MSSA, MRSA) bacteraemia.